Opinion: Patient advocacy groups and innovators must partner to advance new treatments
People living with debilitating conditions and life-threatening diseases are often put in the terrible position of having to wait — even though they lack the luxury of time — for scientific advances that take years to reach the market, preventing them from accessing their much-needed benefits.
A remedy is coming from an unexpected and long-underutilized source: partnerships between patient advocacy groups and pharmaceutical and medical device companies.
